摘要特立帕肽是一种注射用人重组甲状旁腺素,已在全球范围内被批准用于治疗骨质疏松症,在2011年进入中国.临床前研究显示,通过不同于包括双膦酸盐、选择性雌激素受体调节剂(selective estrogen receptor modulators,SERMs)、降钙素和雌激素在内的其他抗骨吸收药物的独特作用机制,特立帕肽可起到促进骨形成的作用.在男性和绝经后妇女中进行的临床试验已证实特立帕肽有成骨作用,并可降低骨折风险,升高骨转换标志物(包括血清骨钙素和Ⅰ型前胶原N末端肽[procollagen type Ⅰ N-terminal propeptide,PINP]、骨密度[bone mineral density,BMD])及改善骨质量.最近,在亚裔人群中进行的临床试验也已得出相似结论,并证实与目前的抗骨吸收药物相比,特立帕肽可提高骨标志物和骨密度.

abstractsTeriparatide is an injectable recombinant human parathyroid hormone (1-34) [rhPTH(1-34)],which has been approved for the treatment of osteoporosis worldwide,including China since 2011.In pre-clinical studies,teriparatide was shown to exhibit anabolic effects on bone with a unique mechanism of action that is distinct from that of antiresorptive agents,including bisphosphonates,selective estrogen receptor modulators (SERMs),calcitonin,and estrogen.This bone-building effect has been supported by clinical trials in men and postmenopausal women,with reductions in fracture risk,and increases in bone turnover markers,including serum osteocalcin and procollagen type Ⅰ N-terminal propeptide (PINP),and bone mineral density (BMD),and improvements in bone quality.Recent studies in Asian patient populations show similar results and support the findings for bone markers and BMD when compared with current antiresorptive medications.